Ken Griffin
SMMT icon

Ken Griffin’s Summit Therapeutics SMMT Stock Holding History

Ken Griffin’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.38M Sell
441,743
-2,033,965
-82% -$32.9M ﹤0.01% 3504
2025
Q4 		$43.3M Buy
2,475,708
+2,272,996
+1,121% +$42.8M 0.01% 1555
2025
Q3 		$4.19M Buy
202,712
+100,295
+98% +$2.43M ﹤0.01% 4678
2025
Q2 		$2.18M Sell
102,417
-896,323
-90% -$20.4M ﹤0.01% 5548
2025
Q1 		$19.3M Buy
998,740
+811,333
+433% +$16.3M ﹤0.01% 2084
2024
Q4 		$3.34M Sell
187,407
-463,426
-71% -$8.98M ﹤0.01% 4655
2024
Q3 		$14.3M Buy
+650,833
New +$9.1M ﹤0.01% 2437
2024
Q2 		– Sell
-5
Closed -$27 – 15304
2024
Q1 		$21 Buy
+5
New +$20 ﹤0.01% 14453
2023
Q2 		– Sell
-22,381
Closed -$39.2K – 15149
2023
Q1 		$39.2K Sell
22,381
-25,997
-54% -$70.9K ﹤0.01% 12453
2022
Q4 		$206K Buy
+48,378
New +$88K ﹤0.01% 10088
2022
Q3 		– Sell
-56,743
Closed -$64.2K – 13535
2022
Q2 		$57K Buy
+56,743
New +$79.5K ﹤0.01% 11849
2022
Q1 		– Sell
-42,593
Closed -$107K – 14497
2021
Q4 		$115K Buy
+42,593
New +$205K ﹤0.01% 12577
2021
Q3 		– Sell
-25,618
Closed -$184K – 14583
2021
Q2 		$191K Sell
25,618
-16,973
-40% -$111K ﹤0.01% 12216
2021
Q1 		$250K Buy
42,591
+26,421
+163% +$170K ﹤0.01% 11233
2020
Q4 		$76K Buy
+16,170
New +$68.5K ﹤0.01% 10370
2019
Q2 		– Sell
-23,783
Closed -$44K – 9790
2019
Q1 		$44K Buy
23,783
+5,782
+32% +$9.48K ﹤0.01% 8875
2018
Q4 		$21K Buy
+18,001
New +$28K ﹤0.01% 8736

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ken Griffin's SMMT Position: Q1 2026 in Review

Ken Griffin reduced its Summit Therapeutics (SMMT) stake by 82% in Q1 2026, selling an estimated $32.9M and leaving 441,743 shares worth $8.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Ken Griffin first reported a position in SMMT in Q4 2018 and has held it in 17 quarters since. The position peaked at $43.3M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Ken Griffin held 441,743 shares of Summit Therapeutics worth $8.38M as of Q1 2026.
  • Ken Griffin sold 2,033,965 Summit Therapeutics shares in Q1 2026, an estimated $32.9M.
  • Summit Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3504 holding.
  • Ken Griffin first reported a position in Summit Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • Ken Griffin's Summit Therapeutics position peaked at $43.3M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.